Enhanced Engraftment of HTLV-I-Infected Human T Cells in Severe Combined Immunodeficiency Mice by Anti-asialo GM-1 Antibody Treatment
-
- ISHIHARA Shiro
- Second Department of Internal Medicine, Miyazaki Medical College
-
- OKAYAMA Akihiko
- Second Department of Internal Medicine, Miyazaki Medical College
-
- NAGATOMO Yasuhiro
- Second Department of Internal Medicine, Miyazaki Medical College
-
- MURAI Koichi
- Second Department of Internal Medicine, Miyazaki Medical College
-
- YAMASHITA Ryozo
- Second Department of Internal Medicine, Miyazaki Medical College
-
- OKAMOTO Masayuki
- Second Department of Internal Medicine, Miyazaki Medical College
-
- SHIMA Takashi
- Second Department of Internal Medicine, Miyazaki Medical College
-
- SASAKI Takashi
- Second Department of Internal Medicine, Miyazaki Medical College
-
- MUELLER Nancy
- Department of Epidemiology, Harvard School of Public Health
-
- TACHIBANA Nobuyoshi
- Second Department of Internal Medicine, Miyazaki Medical College
-
- TSUBOUCHI Hirohito
- Second Department of Internal Medicine, Miyazaki Medical College
この論文をさがす
抄録
The effects of anti-asialo GM-1 antibody (AAGM) treatment on the engraftment of human T-cell leukemia virus type I (HTLV-I)-infected human T cells in severe combined immunodeficiency (SCID) mice were studied. The frequency of tumor formation in an HTLV-I-transformed human T-cell line, MT-2 cells, at the site of inoculation was significantly higher in AAGM-treated than untreated mice (P<0.05): 16/18 (89%) and 16/26 (62%), respectively. The promotive effect of AAGM treatment on tumor development was marked in the early stage (less than 3 weeks), suggesting that the immediate reaction of natural killers to the inoculated cells may be important for the prevention of tumor development. The surface phenotypes and clonality of the tumor cells were the same as the MT-2 cells inoculated. Inoculation of peripheral blood mononuclear cells (PBMC) from one of the 4 adult T-cell leukemia/lymphoma (ATL) patients resulted in the development of tumors in AAGM-treated SCID mice. However, the surface phenotypes of the cells from these tumors were a mixture of B cells and T cells, suggesting that these tumors consisted of Epstein-Barr virus-transformed B cells and HTLV-I-transformed T cells. In addition, HTLV-I was detected by polymerase chain reaction in various organs of the mice inoculated with PBMC from the ATL patient and the asymptomatic carrier examined. These results suggest that elimination of natural killer function by AAGM treatment is important, although such treatment is not always necessary for the engraftment of HTLV-I-infected cells in SCID mice.
収録刊行物
-
- Microbiology and immunology
-
Microbiology and immunology 40 (1), 39-44, 1996-01-20
財団法人 学会誌刊行センター
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1570572699249068416
-
- NII論文ID
- 10004786807
-
- NII書誌ID
- AA00738350
-
- ISSN
- 03855600
-
- 本文言語コード
- en
-
- データソース種別
-
- CiNii Articles